Capital Advisors Ltd. LLC Buys 28 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Capital Advisors Ltd. LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% in the first quarter, HoldingsChannel.com reports. The fund owned 1,212 shares of the medical research company’s stock after purchasing an additional 28 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Thermo Fisher Scientific were worth $704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Gotham Asset Management LLC grew its holdings in Thermo Fisher Scientific by 47.5% in the 3rd quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock valued at $1,343,000 after buying an additional 855 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its position in Thermo Fisher Scientific by 54.3% during the third quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock worth $6,128,000 after acquiring an additional 4,260 shares during the period. Insigneo Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 26.9% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,846 shares of the medical research company’s stock valued at $935,000 after purchasing an additional 391 shares during the period. Axxcess Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 51.6% during the third quarter. Axxcess Wealth Management LLC now owns 21,827 shares of the medical research company’s stock worth $11,048,000 after purchasing an additional 7,427 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Thermo Fisher Scientific by 5.9% in the third quarter. Adage Capital Partners GP L.L.C. now owns 334,124 shares of the medical research company’s stock valued at $169,124,000 after buying an additional 18,739 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock valued at $12,532,780 in the last three months. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 1.5 %

Shares of NYSE:TMO traded down $8.09 during midday trading on Tuesday, hitting $533.63. 947,171 shares of the company’s stock were exchanged, compared to its average volume of 1,546,262. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a market cap of $203.70 billion, a PE ratio of 34.32, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a 50 day moving average price of $574.71 and a 200-day moving average price of $563.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Analysts Set New Price Targets

TMO has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upped their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Barclays cut their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, HSBC upped their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $606.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.